Peapod Bio, a leader in innovative assay development and high-throughput screening (HTS) solutions, has announced a strategic collaboration with Enamine, a global supplier of high-quality small molecule libraries.

The partnership gives Peapod Bio clients fully integrated screening campaigns and access to nearly five million compounds from Enamine, dramatically speeding up hit discovery.

Peapod Bio’s proprietary technologies, including its affinity selection mass spectrometry (ASMS) platform powered by polymeric enrichment arrays, can efficiently identify inhibitors and binding molecules for virtually any target. Enamine complements this with follow-up chemistry to validate and optimize leads.

“This collaboration brings together complementary strengths, exceptional chemistry and cutting-edge screening solutions,” said Dr. Zachary Gurard-Levin, CEO of Peapod Bio. “Together, we’re advancing comprehensive drug discovery solutions.”

“Partnering with Peapod Bio extends the reach of our libraries to new discovery platforms,” added Iryna Iavniuk, CEO of Enamine, US. “Our combined expertise will help researchers accelerate the identification of high value starting points for drug development.”